Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD

PHASE3RecruitingINTERVENTIONAL
Enrollment

504

Participants

Timeline

Start Date

July 25, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

Buagafuran capsules, 15mg/ capsule

Subjects took Buagafuran capsules; twice per day, respectively, after breakfast and dinner for 8 weeks;

DRUG

Buagafuran capsules mimic, 0mg/ capsule

Subjects took Buagafuran capsules mimic. twice per day, respectively, after breakfast and dinner for 8 weeks;

Trial Locations (1)

102600

RECRUITING

Beijing Union Pharmaceutical Factory Ltd, Beijing

All Listed Sponsors
collaborator

R&G Pharma Studies Co.,Ltd.

INDUSTRY

lead

Beijing Union Pharmaceutical Factory Ltd

INDUSTRY

NCT06243640 - Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD | Biotech Hunter | Biotech Hunter